We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

Back to rankings

127 hedge funds and large institutions have $360M invested in Synergy Pharmaceuticals, Inc Common Stock in 2015 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 48 increasing their positions, 35 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more call options, than puts

Call options by funds: $5.19M | Put options by funds: $3M

37% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 35

5% more capital invested

Capital invested by funds: $343M → $360M (+$16.9M)

0% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 19

2% less funds holding

Funds holding: 129 → 127 (-2)

Holders
127
Holders Change
-2
Holders Change %
-1.55%
% of All Funds
3.33%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
19
Increased
48
Reduced
35
Closed
19
Calls
$5.19M
Puts
$3M
Net Calls
+$2.19M
Net Calls Change
+$700K

Top Buyers

Rank Fund Capital Flow
1
TS
Twin Securities
New York
+$8.81M
2
EI
EAM Investors
California
+$3.95M
3
MCM
Moore Capital Management
New York
+$2.68M
4
GPP
Great Point Partners
Connecticut
+$2.51M
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.42M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$8.66M
2
State Street
State Street
Massachusetts
-$7.86M
3
UBS AM
UBS AM
Illinois
-$3.57M
4
PC
PointState Capital
New York
-$3M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.59M
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$2.4M +$165K +27,037 +7%
Renaissance Technologies
27
Renaissance Technologies
New York
$2.25M +$2.42M +397,600 New
NIP
28
Nicholas Investment Partners
California
$2.24M -$805K -132,127 -25%
PVI
29
Pura Vida Investments
New York
$2.11M -$166K -27,200 -7%
TCIM
30
TIAA CREF Investment Management
New York
$2M -$248K -40,755 -10%
BIM
31
BlackRock Investment Management
Delaware
$1.99M +$469 +77 +0%
Charles Schwab
32
Charles Schwab
California
$1.94M +$202K +33,129 +11%
HCM
33
Highbridge Capital Management
New York
$1.92M – – –
Goldman Sachs
34
Goldman Sachs
New York
$1.91M +$1.07M +174,745 +108%
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$1.82M +$391K +64,192 +25%
Ameriprise
36
Ameriprise
Minnesota
$1.77M +$132K +21,591 +7%
UBS Group
37
UBS Group
Switzerland
$1.77M +$1.26M +207,398 +198%
ACM
38
Asymmetry Capital Management
California
$1.72M +$610K +100,002 +49%
DCM
39
DAFNA Capital Management
California
$1.67M -$12.2K -2,000 -0.7%
WRF
40
Waddell & Reed Financial
Kansas
$1.67M – – –
WSA
41
Wall Street Associates
California
$1.53M -$1.44M -236,300 -47%
Cambridge Investment Research Advisors
42
Cambridge Investment Research Advisors
Iowa
$1.41M -$17.5K -2,875 -1%
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$1.39M +$2.27K +372 +0.2%
KCM
44
Kingdon Capital Management
New York
$1.3M -$674K -110,580 -33%
CS
45
Credit Suisse
Switzerland
$1.28M +$238K +39,038 +21%
Axa
46
Axa
France
$1.25M +$627K +102,920 +88%
RFC
47
Russell Frank Company
Washington
$1.22M -$25.7K -4,211 -2%
CPM
48
Chesapeake Partners Management
Maryland
$1.18M – – –
AllianceBernstein
49
AllianceBernstein
Tennessee
$1.12M – – –
OAM
50
Oxford Asset Management
United Kingdom
$1.1M +$1.19M +194,406 New
1
2
3 4 5

SGYP Hedge Fund Activity: Q4 2015 in Review

127 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q4 2015, worth a combined $360M — up 4.9% from $343M a quarter earlier.

Fund positioning in SGYP was balanced in Q4 2015: 19 funds opened new positions, 19 closed out, 48 added to existing stakes and 35 trimmed.

The largest buyer was Twin Securities, opening a new position worth an estimated $8.81M. The largest seller was Citadel Advisors, cutting an estimated $8.66M.

  • 127 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q4 2015, down from 129 in Q3 2015.
  • Funds reported $360M of Synergy Pharmaceuticals, Inc Common Stock stock for Q4 2015, up 4.9% quarter-over-quarter.
  • 19 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q4 2015 and 19 closed out, a net change of 0 holders.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q4 2015 was Twin Securities, an estimated $8.81M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q4 2015 was Citadel Advisors, an estimated $8.66M sold.

Based on aggregated 13F filings for Q4 2015.